Epstein Secrets

ized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.1 <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular risk according

ized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 0.9 Lower relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

ized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

heart disease. CHOL/HDLC RATIO 8.4 H NON HDL CHOLESTEROL 186 H Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.8 Lower relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

ized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 mg/dL (talc) <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular r

Range NEGATIVE < OR = 5 /HPF < OR - 2 /HPF < OR - 5 /HPF NONE SEEN /HPF NONE SEEN /LPF 200-1100 pg/mL Lab This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

ease. CHD or with CHOL/HDLC RATIO 4.8 NON HDL CHOLESTEROL 113 Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.9 Lower relative cardiovascular risk according to Ama/cnc guidelines. FOr ages >17 ha-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

ized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk

Range NEGATIVE < OR = 5 /HPF < OR - 2 /HPF < OR - 5 /HPF NONE SEEN /HPF NONE SEEN /LPF 200-1100 pg/mL Lab This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not

ease. CHD or with CHOL/HDLC RATIO 4.8 NON HDL CHOLESTEROL 113 Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.9 Lower relative cardiovascular risk according to Ama/cnc guidelines. FOr ages >17 ha-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A